Page 1

karo pharma Year - end report 2020 Q4 , October - December ● ● ● * Karo Pharma AB Visiting address : Klara Norra Kyrkogata 33 111 22 Stockholm , Sweden Net sales amounted to MSEK 721.2 ( 649.3 ) . This corresponds to an increase of 11 % for the period . The organic growth * during the fourth quarter was + 1 % . The currency impact in the quarter was -1 % while the acquisitions of the product portfolios Proct from Leo Pharma and Pevaryl® from Johnson & Johnson generated growth of 11 % . info@karopharma.se karopharma.com EBIT ( Operating Profit ) amounted to MSEK -19.4 ( 8.2 ) . Adjusted EBITDA * amounted to MSEK 164.8 ( 151.4 ) corresponding to growth of 9 % excluding non recurring items related to acquired product portfolios totalling MSEK -53.4 ( -43.7 ) . Cash flow from operating activities amounted to MSEK 104.8 ( -10.8 ) . Earnings per share was SEK -0.12 ( -0.11 ) , before and after dilution . Alternative Financial Ratios ( APM ) , note 4 for further information . Page 1/19 The gross margin , defined as gross profit divided by net sales , was 49.3 % ( 46.8 % ) for the quarter . The margin was affected positively by the acquired product portfolios . 1 During the period Karo Pharma divested the Hospital Supply business to J2L . The transaction closed on December 1 , 2020. The net gain of the divestment was MSEK 5.2 and the cash flow effect MSEK 151.0 .